43 completed, 13 unknown, 11 recruiting, 10 terminated. 91 Phase 3, 7 Phase 2.
Follow Lymphoma, T-Cell: new trials by email Literature Review of Lymphoma, T-Cell trials Research Report on Lymphoma, T-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma Sugemalimab, Placebo, Pegaspargase - Extranodal NK/T-cell Lymphoma | Phase 3 | Not yet recruiting | CStone Pharmaceuticals | 150 | 2027-06-01 | 2026-05-27 |
| BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL GELAD regimen, MEDA regimen, LEAP regimen - Extranodal NK/T-cell Lymphoma | Phase 3 | Recruiting | Rong Tao | 150 | 2026-08-11 | 2026-08-13 |
| TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma TR115, Investigator's Choice - PTCL, NK T-Cell Lymphoma | Phase 3 | Not yet recruiting | Tarapeutics Science Inc. | 180 | 2026-07-30 | 2026-06-10 |
| Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma PET-CTandct- DNAdetection, golidocitinib, Placebo - Maintenance Treatment of Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Fudan University | 136 | 2026-03-27 | 2026-03-31 |
| Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy golidocitinib, Placebo - Peripheral T Cell Lymphoma | Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 68 | 2026-02-15 | 2026-02-24 |
| A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma Cidabenamine, Azacitidine - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 40 | 2026-02-01 | 2026-02-05 |
| Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance Brentuximab Vedotin (Bv), Placebo - Cutaneous T Cell Lymphoma (CTCL), Brentuximab Vedotin | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 84 | 2025-11-01 | 2025-09-17 |
| Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone), Tucidinostat, Placebo - Lymphoma, T-Cell, Peripheral | Phase 3 | Recruiting | Chipscreen Biosciences, Ltd. | 224 | 2025-08-12 | 2026-10-21 |
| Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection - Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma | Phase 3 | Recruiting | Eastern Cooperative Oncology Group | 294 | 2025-06-18 | 2026-11-16 |
| A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype Duvelisib, Gemcitabine, Bendamustine - Lymphoma | Phase 3 | Recruiting | SecuraBio | 124 | 2025-05-19 | 2026-04-06 |
| A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL. P-GEMD, P-Gemox - NK-T-Cell Lymphoma, Extranodal | Phase 3 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 60 | 2025-05-01 | 2025-05-01 |
| A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma XNW5004 ; Chidamide placebo, XNW5004 placebo; Chidamide - Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 3 | Recruiting | Evopoint Biosciences Inc. | 120 | 2025-04-10 | 2026-01-09 |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Hypericin, Placebo - CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Terminated | Soligenix | 70 | 2025-01-07 | 2026-07-13 |
| Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma Soquelitinib, Belinostat, Pralatrexate - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma | Phase 3 | Recruiting | Corvus Pharmaceuticals, Inc. | 150 | 2024-10-02 | 2026-09-25 |
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma Linperlisib - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai YingLi Pharmaceutical Co. Ltd. | 606 | 2024-09-10 | 2024-08-12 |
| A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) Golidocitinib, Chidamide, Gemcitabine - Peripheral T-cell Lymphoma | Phase 3 | Recruiting | Dizal Pharmaceuticals | 218 | 2024-05-13 | 2026-06-08 |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL Belinostat Injection, Pralatrexate Injection, CHOP - Peripheral T Cell Lymphoma | Phase 3 | Active not recruiting | Acrotech Biopharma Inc. | 504 | 2023-10-04 | 2026-10-15 |
| ChiCGB vs BEAM in High-risk or R/R Lymphomas Chidamide, Cladribine, Gemcitabine - Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell | Phase 3 | Unknown | Sichuan University | 306 | 2022-07-01 | 2022-07-25 |
| TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides Low-dose total-skin electron-beam therapy, Phototherapy - Mycosis Fungoides, Cutaneous T Cell Lymphoma | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 78 | 2022-02-01 | 2022-01-25 |
Showing 20 of 91. Sign in to see all of them.
Lymphoma, T-Cell, Cutaneous (38) · Lymphoma (35) · Lymphoma, Large B-Cell, Diffuse (34) · Lymphoma, Non-Hodgkin (33) · Lymphoma, Large-Cell, Anaplastic (32) · Mycosis Fungoides (32) · Lymphoma, Mantle-Cell (30) · Burkitt Lymphoma (29) · Lymphoma, B-Cell, Marginal Zone (29) · Lymphoma, Follicular (29) · Lymphoma, Large-Cell, Immunoblastic (29) · Leukemia, Lymphocytic, Chronic, B-Cell (27) · Sezary Syndrome (27) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (26) · Hodgkin Disease (25)
Neoplasms by Histologic Type (90) · Hemic and Lymphatic Diseases (84) · Immune System Diseases (84) · Immunoproliferative Disorders (84) · Lymphatic Diseases (84) · Neoplasms (80) · Lymphoproliferative Disorders (76) · Lymphoma, Non-Hodgkin (58) · Lymphoma (56) · Lymphoma, B-Cell (34) · Hematologic Diseases (31) · DNA Virus Infections (30) · Herpesviridae Infections (30) · Leukemia, Lymphoid (30)
Cyclophosphamide (18) · Doxorubicin (17) · Vincristine (16) · Prednisone (15) · Gemcitabine (9) · Etoposide (8) · Methotrexate (7) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (7) · 10-propargyl-10-deazaaminopterin (6) · Radiotherapy (6) · Rituximab (5) · Brentuximab Vedotin (4) · Cytarabine (4) · Dexamethasone (4) · Filgrastim (4)
European Organisation for Research and Treatment of Cancer - EORTC (6) · Fred Hutchinson Cancer Center (3) · German High-Grade Non-Hodgkin's Lymphoma Study Group (3) · Jonsson Comprehensive Cancer Center (3) · Alliance for Clinical Trials in Oncology (2) · Assistance Publique - Hôpitaux de Paris (2) · Eisai Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · Millennium Pharmaceuticals, Inc. (2) · NCIC Clinical Trials Group (2) · Ruijin Hospital (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) · Soligenix (2) · Aarhus University Hospital (1) · Acrotech Biopharma Inc. (1)
United States (39) · China (19) · Germany (19) · Italy (15) · France (14) · United Kingdom (14) · Spain (13) · Belgium (12) · Canada (11) · Australia (10) · Switzerland (9) · Austria (8) · Israel (8) · Denmark (7) · Netherlands (7)
John A. Glaspy, MD, MPH (2) · Michael G.M. Pfreundschuh, MD † (2) · Viola Poeschel, MD (2) · Abhay Patki, PhD (1) · Barry J.A. Laird, MD (1) · Charles L. Loprinzi, MD (1) · Chean Eng Ooi (1) · Chuanxu Liu, MD & PhD (1) · Daniel C. Betticher, MD (1) · Daobin Zhou (1) · David J. Straus, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Dmitri O. Grebennik, MD (1)
PMID 32632956, PMID 20679620, PMID 25113753, PMID 15459300, PMID 16148284, PMID 16710026, PMID 16888080, PMID 17397698, PMID 18226581, PMID 18293016, PMID 19139435, PMID 21280197, PMID 21444917, PMID 21599590, PMID 22337718, PMID 22480131, PMID 22811078, PMID 22924950, PMID 23335369, PMID 24493716, PMID 24991715, PMID 25135997, PMID 25135998, PMID 25156886, PMID 25267740, PMID 25403207, PMID 25482745, PMID 26109202, PMID 26700120, PMID 26700123, PMID 27020837, PMID 27993811, PMID 28273702, PMID 28398499, PMID 28516671, PMID 28600132, PMID 28787259, PMID 28935847, PMID 29072976, PMID 29097500, PMID 30100375, PMID 30522922, PMID 30694529, PMID 30707661, PMID 30892603, PMID 30904980, PMID 31123029, PMID 31526286, PMID 31868632, PMID 32396614
2004 (1), 2009 (1), P30CA015083 (1), P30CA036727 (1), P30CA068485 (1), P30CA069533 (1), R01CA112631 (1), R01CA127655 (1), U10CA081920 (1), U10CA180820 (1)